'Venture philanthropy' has become a buzz term in the nonprofit sector over the past decade, but the concept was completely new to disease-focused charities when the Cystic Fibrosis Foundation decided to give it a try in 1998. Frustrated by the lack of progress toward targeted therapies for cystic fibrosis-a rare disease that afflicts just 70,000 people worldwide-Robert J. Beall, president and chief executive of the Bethesda, Maryland-based organization, added a bold new component to the foundation's research-funding strategy. Beall, who joined the foundation in 1980, launched a program aimed at absorbing the early financial risk involved in drug development as a way to entice for-profit companies to get involved in cystic fibrosis research.
展开▼
机译：在过去的十年中，“公益创投”在非营利组织中已成为热门话题，但当囊性纤维化基金会于1998年决定对其进行尝试时，这个概念对于以疾病为中心的慈善机构来说是全新的。由于缺乏进展，对此感到沮丧囊性纤维化的靶向疗法-一种罕见的疾病，仅在全球范围内折磨着70,000人-马里兰州贝塞斯达的组织总裁兼首席执行官罗伯特·J·比尔（Robert J. Beall）在基金会的研究资助策略中增加了一个大胆的新组成部分。 Beall于1980年加入该基金会，他发起了一项旨在吸收与药物开发有关的早期财务风险的计划，以此吸引营利性公司参与囊性纤维化研究。
展开▼
